<DOC>
	<DOCNO>NCT00485901</DOCNO>
	<brief_summary>The purpose study compare intramuscular Olanzapine intramuscular Haloperidol change agitation patient schizophrenia</brief_summary>
	<brief_title>Comparison Intramuscular Olanzapine Intramuscular Haloperidol Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Male female patient , age 18 65 Patients must diagnosis schizophrenia meet disease diagnostic criterion define DSMIV Patients must consider , investigator , clinically agitated appropriate candidate treatment IM medication . Investigator must believe safe administer IM olanzapine IM comparator patient respect safety profile drug ( include anticholinergic property Olanzapine IM comparator agent ) Subjects ' illness must , opinion investigator , cause substance abuse Patient must hospitalize study Previous participation ( treatment study drug ) Lilly sponsor intramuscular olanzapine clinical trial Serious , unstable illness death anticipate within 1 year intensive care unit hospitalization disease anticipate within 6 month Have know diagnosis dementia type , define DSMIV DSMIVTR Documented history allergic reaction study medication ( ) Treatment injectable depot neuroleptic within 1 injection interval prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>